Literature DB >> 15536230

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.

Arne Astrup1, Ian Caterson, Pierre Zelissen, Bernard Guy-Grand, Michele Carruba, Brian Levy, Xiang Sun, Martin Fitchet.   

Abstract

OBJECTIVE: To examine the safety and efficacy of topiramate (TPM) for maintaining weight following a low-calorie diet. RESEARCH METHODS AND PROCEDURES: Obese subjects (30 < or = BMI < 50 kg/m(2)) 18 to 75 years old received a low-calorie diet for 8 weeks. Those who lost > or =8% of their initial weight received TPM (96 or 192 mg/d) or placebo; all were on a lifestyle modification plan. Sixty weeks of medication were planned. Sponsor ended study early to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. Efficacy was analyzed in subjects who completed 44 weeks of treatment before study termination.
RESULTS: Of the 701 subjects enrolled, 80% lost > or =8% of their initial body weight and were randomized; 293 were analyzed for efficacy. Most withdrawals were due to premature termination of the study. Subjects receiving TPM lost 15.4% (96 mg/d) and 16.5% (192 mg/d) of their enrollment weight by week 44, compared with 8.9% in the placebo group (p < 0.001). Subjects on TPM continued to lose weight after the run-in, whereas those on placebo regained weight. Significantly more TPM subjects lost 5%, 10%, or 15% of their randomization weight than placebo. Most adverse events were related to the central nervous system. DISCUSSION: During a treatment period of 44 weeks, TPM was generally well tolerated, and subjects maintained weight loss initially achieved by a low-calorie diet-and produced additional clinically significant weight loss beyond that achieved by a low-calorie diet.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536230     DOI: 10.1038/oby.2004.206

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  23 in total

Review 1.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.

Authors:  Angelo Tremblay; Jean-Philippe Chaput; Sonia Bérubé-Parent; Denis Prud'homme; Claude Leblanc; Natalie Alméras; Jean-Pierre Després
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

3.  Teledietetics improves weight reduction by modifying eating behavior: a randomized controlled trial.

Authors:  Louisa Ming Yan Chung; Queenie Pui Sze Law; Shirley Siu Ming Fong; Joanne Wai Yee Chung
Journal:  Telemed J E Health       Date:  2013-11-08       Impact factor: 3.536

4.  Topiramate for weight reduction in adolescents with severe obesity.

Authors:  Claudia K Fox; Kara L Marlatt; Kyle D Rudser; Aaron S Kelly
Journal:  Clin Pediatr (Phila)       Date:  2014-07-14       Impact factor: 1.168

Review 5.  Neural control of energy balance: translating circuits to therapies.

Authors:  Laurent Gautron; Joel K Elmquist; Kevin W Williams
Journal:  Cell       Date:  2015-03-26       Impact factor: 41.582

Review 6.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

Review 7.  Behavioral and pharmacologic therapies for obesity.

Authors:  Marion L Vetter; Lucy F Faulconbridge; Victoria L Webb; Thomas A Wadden
Journal:  Nat Rev Endocrinol       Date:  2010-08-03       Impact factor: 43.330

8.  Synchronous neuronal interactions in rat hypothalamic culture: a novel model for the study of network dynamics in metabolic disorders.

Authors:  Vijayakumar Mavanji; Apostolos P Georgopoulos; Catherine M Kotz
Journal:  Exp Brain Res       Date:  2021-01-03       Impact factor: 1.972

Review 9.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

10.  Zonisamide decreases ethanol intake in rats and mice.

Authors:  Clifford M Knapp; Melissa Mercado; Tara Lynn Markley; Steven Crosby; Domenic A Ciraulo; Conan Kornetsky
Journal:  Pharmacol Biochem Behav       Date:  2007-04-11       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.